Cargando…
Development of vaccines for SARS-CoV-2
COVID-19 emerged in late 2019 and has rapidly spread through many countries globally. The causative SARS-CoV-2 virus was not known until recently, and there is little or no natural immunity in human populations. There is an urgent need for vaccines and drugs to combat this new pandemic. In just a fe...
Autores principales: | Ng, Wern Hann, Liu, Xiang, Mahalingam, Suresh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
F1000 Research Limited
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431966/ https://www.ncbi.nlm.nih.gov/pubmed/32850116 http://dx.doi.org/10.12688/f1000research.25998.1 |
Ejemplares similares
-
Can live-attenuated SARS-CoV-2 vaccine contribute to stopping the pandemic?
por: Tang, Patrick Chun Hean, et al.
Publicado: (2022) -
Comorbidities in SARS-CoV-2 Patients: a Systematic Review and Meta-Analysis
por: Ng, Wern Hann, et al.
Publicado: (2021) -
The Delta SARS-CoV-2 Variant of Concern Induces Distinct Pathogenic Patterns of Respiratory Disease in K18-hACE2 Transgenic Mice Compared to the Ancestral Strain from Wuhan
por: Liu, Xiang, et al.
Publicado: (2022) -
SARS-CoV-2 virus: Vaccines in development
por: Huang, Qingrui, et al.
Publicado: (2021) -
Vaccines and Therapies in Development for SARS-CoV-2 Infections
por: Wu, David, et al.
Publicado: (2020)